The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced ...
A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including ...
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published study showed that patients with relapsing multiple sclerosis (RMS) who started ocrelizumab (Ocrevus; ...
A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results